Reimagine Medicine | Novartis United States of America

Media Release
Apr 11, 2011
Novartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows
Media Release
Mar 08, 2011
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
Media Release
Jan 10, 2011
Important Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
Media Release
May 25, 2011
Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid
Media Release
May 24, 2011
Novartis teams up with Phil Keoghan, host of “The Amazing Race,” to raise awareness for multiple sclerosis through inspirational national bike tour
Media Release
May 07, 2011
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Media Release
Sep 16, 2011
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
Media Release
Aug 01, 2011
FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity
Media Release
Jul 01, 2011
Novartis receives FDA approval for Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Media Release
Sep 26, 2011
Novartis Drug Afinitor® Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing
Media Release
Sep 25, 2011
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Media Release
Sep 23, 2011
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial

‹ Previous page
1
…
29
30
31
32
33
34
35
…
50
› Next page